GlassScriptPhysician profile
Travis Charles Geraci
NPI 1508127036
$3,603.86
in general payments reported to CMS, 2019-2025
12 companies · $922 in 2025
The $922 reported for 2025 was more than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
See the full distribution for Thoracic Surgery (Cardiothoracic Vascular Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $400 · 2021: $921 · 2022: $575 · 2023: $118 · 2024: $79.99 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $900 · Food and Beverage: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $900.00 |
| Food and Beverage | $219.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $1,100.07 | 2020-2021 | |
| Maquet Cardiopulmonary Gmbh | $900.00 | 2025 | Hls Set |
| Edwards Lifesciences Corporation | $538.39 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $409.71 | 2022-2025 | Tagrisso |
| Abbott Laboratories | $226.49 | 2019 | |
| Intuitive Surgical, INC. | $125.05 | 2020-2022 | |
| Ge Healthcare | $104.19 | 2022 | |
| Atricure, INC. | $78.20 | 2022-2024 | |
| Astellas Pharma US INC | $64.57 | 2023-2024 | Cresemba |
| Amgen INC. | $24.63 | 2022 | |
| Zimmer Biomet Holdings, INC. | $19.53 | 2023 | Sternalock Blu System, Pectus Bar Bending Forceps, Standard |
| Medtronic, INC. | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Geraci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.